Trastuzumab combination and monotherapy for HER2 advanced or recurrent uterine or endometrial cancer : a review of clinical effectiveness and cost-effectiveness / Casey Gray, Charlene Argáez
. In order to support decision-making on the use of trastuzumab monotherapy or trastuzumab combination therapy in patients with HER2-positive advanced or recurrent uterine or endometrial cancer, the purpose of this report is to summarize and critically appraise the relevant evidence regarding the clinical effectiveness and cost-effectiveness of trastuzumab combination therapy or trastuzumab monotherapy for HER2 positive advanced or recurrent uterine or endometrial cancer..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
November 11, 2020 |
|---|---|
| Erschienen: |
Ottawa: Canadian Agency for Drugs and Technologies in Health ; November 11, 2020 |
| Ausgabe: |
Version: 1.0. |
| Reihe: |
CADTH rapid response report: summary with critical appraisal |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gray, Casey [VerfasserIn] |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Cost-Benefit Analysis |
|---|
| Anmerkungen: |
Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed September 8, 2021) |
|---|
| Umfang: |
1 online resource (1 PDF file (20 pages)) ; illustration. |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1773181815 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1773181815 | ||
| 003 | DE-627 | ||
| 005 | 20230428011901.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211011s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1773181815 | ||
| 035 | |a (DE-599)KEP06872246X | ||
| 035 | |a (NCBI)9917766893406676 | ||
| 035 | |a (EBP)06872246X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gray, Casey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Trastuzumab combination and monotherapy for HER2 advanced or recurrent uterine or endometrial cancer |b a review of clinical effectiveness and cost-effectiveness |c Casey Gray, Charlene Argáez |
| 250 | |a Version: 1.0. | ||
| 264 | 1 | |a Ottawa |b Canadian Agency for Drugs and Technologies in Health |c November 11, 2020 | |
| 300 | |a 1 online resource (1 PDF file (20 pages)) |b illustration. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a CADTH rapid response report: summary with critical appraisal | |
| 500 | |a Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed September 8, 2021) | ||
| 520 | |a . In order to support decision-making on the use of trastuzumab monotherapy or trastuzumab combination therapy in patients with HER2-positive advanced or recurrent uterine or endometrial cancer, the purpose of this report is to summarize and critically appraise the relevant evidence regarding the clinical effectiveness and cost-effectiveness of trastuzumab combination therapy or trastuzumab monotherapy for HER2 positive advanced or recurrent uterine or endometrial cancer. | ||
| 650 | 2 | |a Uterine Neoplasms |x drug therapy |0 http://id.nlm.nih.gov/mesh/D014594Q000188 | |
| 650 | 2 | |a Trastuzumab |x therapeutic use |0 http://id.nlm.nih.gov/mesh/D000068878Q000627 | |
| 650 | 2 | |a Receptor, ErbB-2 |x drug effects |0 http://id.nlm.nih.gov/mesh/D018719Q000187 | |
| 650 | 2 | |a Treatment Outcome |0 http://id.nlm.nih.gov/mesh/D016896 | |
| 650 | 2 | |a Cost-Benefit Analysis |0 http://id.nlm.nih.gov/mesh/D003362 | |
| 655 | 2 | |a Review |0 http://id.nlm.nih.gov/mesh/D016454 | |
| 700 | 1 | |a Argáez, Charlene |e verfasserin |4 aut | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK567200/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 3994078962 |h h64 NCBI |y zi06404 |z 21-10-21 | ||
| 980 | |2 40 |1 01 |x 0007 |b 3994005213 |h OLR-NCB-BOOKSHELF |y xsn |z 21-10-21 | ||
| 980 | |2 74 |1 01 |x 0354 |b 3999781483 |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-11-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3995676863 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 25-10-21 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 3987671300 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 11-10-21 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 3987763256 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 11-10-21 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK567200/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK567200/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK567200/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK567200/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK567200/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||